BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for
heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but …

Background: Dapagliflozin has been shown to reduce morbidity and mortality in Heart
Failure with reduced Ejection Fraction (HFrEF), but its impact on exercise capacity of non …

Background: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Patients with heart failure and preserved ejection fraction (HFpEF) have a high burden of
symptoms and functional limitations, and have a poor quality of life. By targeting …

BACKGROUND: Patients with heart failure (HF) have a high burden of symptoms and
physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 …

Background: Many patients with heart failure and reduced ejection fraction (HFrEF) have
chronic kidney disease that complicates pharmacological management and is associated …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Background: Goals of management in patients with heart failure and reduced ejection
fraction include reducing death and hospitalizations, and improving health status …

Importance Women may respond differently to certain treatments for heart failure (HF) with
reduced ejection fraction (HFrEF) than men. Objective To investigate the efficacy and safety …

Aims The aim of this study was to examine whether left ventricular ejection fraction (LVEF)
modified efficacy and safety of dapagliflozin 10 mg compared with placebo in the 4744 …